PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.

Laboratories

Alta Sciences

APRIL 8, 2025

billion by 2030. These structures resist water-based drugs, limit absorption, and tightly regulate what enters the inner eye. Precedence Research reports that the global ophthalmic drug market size is estimated to double in 10 years, from $34.6 billion in 2021 to an estimated $68.93

Clinical Trials

DrugBank

FEBRUARY 19, 2025

billion by 2030, the sector is witnessing a shift in how drugs are conceived, developed, and tested.  This discovery highlights how AI can uncover new biological insights and enable the development of targeted therapies for diseases with unmet medical needs. billion in 2023 to $7.9

Clinical Trials

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. The role of this type of CRO is pivotal in the drug development process to determine whether a new therapy is well-tolerated in the general population over a longer period of time. What is a Pre-Clinical CRO? over this period.

Clinical Research

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Novartis is taking bold steps to increase patient reach in LMICs with its strategic innovative therapies by at least 200% by 2025.

Therapies

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014.

Disease

The Pharma Data

MARCH 13, 2021

. “A key insight of the results from the TRAILBLAZER-ALZ study is that donanemab not only significantly reduced the amount of amyloid deposition in these patients but also slowed the clinical progression of the disease suggesting that this could be a disease-modifying therapy. Source link:[link].

Disease

BioPharma Drive: Drug Pricing

JULY 23, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. and European regulators in the second half of 2026. You can unsubscribe at anytime. Smith wrote in a note to clients.

Trials

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. In response to this hysteria, regulation was aggressively tightened. Cirsium Bio is using plants to produce viral vectors for gene therapy. The total global bioprocessing capacity was estimated at 17.4

Vaccine

PPD

JANUARY 21, 2025

As 2025 kicks off, the biopharma and biotech industries find themselves at a pivotal juncture, navigating an era of rapid transformation marked by new technological advancements, evolving regulations and shifting industry priorities. This is especially critical in managing complex therapies, where precision and safety are paramount.

Clinical Trials